Review article: The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 5, 2014, Pages 478-487

  Koff, R S ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RIBAVIRIN; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84893735770     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12601     Document Type: Review

References (37)

1. Chen J, Florian J, Carter W, et al,. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-5.
2. Toyoda H, Kumada T, Tada T, et al,. Incidence and risk factors for hepatocellular carcinoma in patient with chronic hepatitis C after the eradication of HCV. Hepatology 2013; 58 (Suppl.): 1168A.
3. Pellicelli AM, Romano M, Stroffolini T, et al,. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol 2012; 12: 162.
4. Massoumy B, Port K, Calle Serrano B, et al,. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharm Ther 2013; 38: 1365-72.
5. Di Bisceglie AM, Kuo A, Rustgi VK, et al,. Virologic outcomes and adherence to treatment algorithms in a longitudinal study of patients with chronic hepatitis C treated with boceprevir (BOC) or telaprevir (TVR) in the United States (HCV-TARGET). Hepatology 2013; 58 (Suppl.): 227A-8A.
6. Backus LI, Belperio PS, Shahoumian TA, et al,. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large US cohort. Aliment Pharmacol Ther 2013; 39: 93-103.
7. Gentile I, Borgia F, Buonomo AR, et al,. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Current Med Chem 2013; 20: 3733-42.
8. Babusis DM, Curry MP, Denning JM, et al,. Nucleotide analog levels in liver explants from HCV infected subjects undergoing liver transplantation after up to 24 weeks sofosbuvir (GS-7977) with ribavirin. Hepatology 2013; 58 (Suppl.): 737A.
9. Lam AM, Espiritu C, Bansal S, et al,. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2013; 56: 3359-68.
10. Rajyaguru S, Xu S, Hebner C, et al,. Sofosbuvir selects the NS5B S282T mutation in vitro in genotype 1-6 replicons and is not cross-resistant to resistant associated variants selected by other classes of antiviral inhibitors. Hepatology 2013; 58 (Suppl.): 739A.
11. Svarovskaia ES, Dvory HS, Hebner C, et al,. No resistance detected in four phase 3 clinical studies in HCV genotype 1-6 of sofosbuvir + ribavirin with or without peginterferon. Hepatology 2013; 58 (Suppl.): 1091A-2A.
12. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al,. Sobosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatology 2013; 58: 663-8.
13. Herbst DA, Reddy KR,. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013; 22: 527-36.
14. Yoshida E, Sulkowski M, Gane E, et al,. The concordance between SVR4, SVR12, and SVR24 in patients with chronic HCV infection who received treatment with sofosbuvir (SOF) in phase 3 clinical trials. Hepatology 2013; 58 (Suppl.): 734A.
15. Lawitz E, Lalezari JP, Hassanein T, et al,. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8.
16. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
17. Kowdley KV, Lawitz E, Crespo I, et al,. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicenter phase 2 trial. Lancet 2013; 38: 2100-7.
18. Osinusi A, Meissner EG, Lee Y-J, et al,. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics. A randomized clinical trial. JAMA 2013; 310: 804-11.
19. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
20. Lalezari J, Lawitz E, Rodriguez-Torres M, et al,. Once daily PSI-7977 plus pegylated IFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. J Hepatol 2011; 54 (Suppl.): S28.
21. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 patients without treatment options. N Engl J Med 2013; 368: 1867-77.
22. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE study. Hepatology 2013; 58 (Suppl.): 733A.
23. Ruane PJ, Ain D, Riad J, et al,. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry. Hepatology 2013; 58 (Suppl.): 736A.
24. Sulkowski MJ, Gardiner D, Rodriguez-Torres M, et al,. High rate of sustained virological response with all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), +/- ribavirin, in treatment naive patients chronically infected with HCV genotype 1, 2 and 3. Hepatology 2012; 56: Abstr. LB#2.
25. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCVgenotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). J Hepatology 2013; 58 (Suppl.): S570. Abstr. 1417.
26. Gane EJ, Stedman CA, Hyland RH, et al,. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin: the ELECTRON trial. Hepatology 2013; 58 (Suppl.): 243A.
27. Lawitz E, Poordad F, Hyland RH, et al,. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin resulted in ≥95% sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: the LONESTAR trial. Hepatology 2013; 58 (Suppl.): 315A-6A.
28. Lawitz E, Poordad FF, Pang PS, et al,. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial. Lancet 2013; doi: 10.1016/S0140-6736(13)62121-2 [Epub ahead of print].
29. Lawitz E, Hebner C, Pang PS, et al,. Once daily sofosbuvir/ledipasvir fixed dose combination is highly effective in subjects with baseline NS5A inhibitor and NS3 protease inhibitor resistance-associated variants: the LONESTAR trial. Hepatology 2013; 58 (Suppl.): 1092A.
30. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al,. SVR results of a once-daily regimen of simeprevir (TM435) plus sofosbuvir (GS-7977) with of without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. Hepatology 2013; 58 (Suppl.): Abstr. LB-3.
31. Curry MP, Forns X, Chung RT, et al,. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013; 58 (Suppl.): 314A-5A.
32. Forns X, Fontana RJ, z Moonka D, et al,. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation. Hepatology 2013; 58 (Suppl.): 732A-3A.
33. Charlton MR, Gane EJ, Manns MP, et al,. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective multicenter study. Hepa-tology 2013; 58 (Suppl.): Abstr. LB-2.
34. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, et al,. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Hepatology 2013; 58 (Suppl.): 313A-4A.
35. Wyles DL, Nelson DR, Swain MG, et al,. On treatment HCV RNA as a predictor of virologic response in sofosbuvir-containing regimens for genotype 2.3 HCV infection: analysis of the FISSION, POSITRON, and FUSION studies. Hepatology 2013; 58 (Suppl.): 750A.
36. Kowdley K, Shiffman M, Sheikh A, et al,. Sofosbuvir + ribavirin with or without peginterferon is well-tolerated and associated with high SVR rates: integrated results from 4 phase 3 trials in genotypes 1-6. Am J Gastroenterology 2013; 108 (Suppl. 1): S123.
37. Patel K, Gordon SC, Sheikh AM, et al,. Efficacy and safety of sofosbuvir in patients according to fibrosis stage: an analysis of phase 3 data. Hepatology 2013; 58 (Suppl.): 738A-9A.